Biotheus, a Chinese start-up that specializes in the discovery and development of therapeutic biologics in the oncology disease space, announced on Wednesday that it has raised over RMB100 million (US$14.51 million) in a series pre-A round of financing led by Chinese healthcare-focused private equity firm Shiyu Capital.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
